Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645892 | 1.00 | MAPK1 (0.61) | MAPK1ACHEDRD2DRD4TDP1 | |
| SCHEMBL14972871 | 1.00 | MAPK1 (0.61) | MAPK1ACHEDRD2DRD4TDP1 | |
| SCHEMBL12463 | 0.94 | ACHE (0.57) | MAPK1ACHEDRD2DRD4TDP1 | |
| SCHEMBL16668774 | 0.89 | TSHR (0.55) | MAPK1TDP1ALDH1A1MAPTKDM4E | |
| SCHEMBL13645864 | 0.88 | DRD2 (0.50) | MAPK1ACHEDRD2DRD4TDP1 | |
| SCHEMBL29381067 | 0.87 | DRD2 (0.62) | MAPK1ACHEDRD2DRD4TDP1 | |
| SCHEMBL27465 | 0.87 | DRD2 (0.62) | MAPK1ACHEDRD2DRD4TDP1 | |
| SCHEMBL20231187 | 0.86 | DRD2 (0.51) | MAPK1DRD2DRD4TDP1L3MBTL1 | |
| SCHEMBL13038702 | 0.86 | ADRB2 (0.50) | MAPK1DRD2DRD4TDP1L3MBTL1 | |
| SCHEMBL23267298 | 0.86 | MAPK1 (0.61) | MAPK1ACHEDRD2DRD4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127375-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127375-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | OPRM1, OPRL1, OPRK1 | MAPK1 1158/4885ACHE 184/4885DRD2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.